CM
SAGE

Castleark Management’s Sage Therapeutics SAGE Stock Holding History

Castleark Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,745
Closed -$1.51M – 387
2019
Q3 		$1.51M Buy
10,745
+3,355
+45% +$561K 0.06% 225
2019
Q2 		$1.35M Buy
+7,390
New +$1.26M 0.05% 234
2018
Q3 		– Sell
-22,950
Closed -$3.59M – 405
2018
Q2 		$3.59M Sell
22,950
-126
-0.5% -$19.8K 0.11% 214
2018
Q1 		$3.72M Sell
23,076
-5,419
-19% -$920K 0.12% 216
2017
Q4 		$4.69M Buy
+28,495
New +$2.76M 0.14% 197

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Castleark Management's SAGE Position: Q4 2019 in Review

Castleark Management sold out of Sage Therapeutics (SAGE) in Q4 2019, closing a stake of 10,745 shares — an estimated $1.51M sold.

Castleark Management first reported a position in SAGE in Q4 2017 and held it in 5 quarters. The position peaked at $4.69M in Q4 2017. 267 funds tracked by Wall St. Rank hold SAGE as of Q4 2019.

  • Castleark Management reported no remaining Sage Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Castleark Management sold 10,745 Sage Therapeutics shares in Q4 2019, an estimated $1.51M.
  • Castleark Management first reported a position in Sage Therapeutics in Q4 2017 and held it in 5 quarters.
  • Castleark Management's Sage Therapeutics position peaked at $4.69M in Q4 2017.
  • 267 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2019.

Based on Castleark Management's 13F filing for Q4 2019, filed 14 Feb 2020.